Tech Company M&A Transactions

LigoCyte Pharmaceuticals Acquisition

On 10/8/2012, LigoCyte Pharmaceuticals was bought by Takeda Pharmaceuticals. The parties disclosed the acquisition price to be $60 million.

Transaction Overview

Announced On
10/8/2012
Transaction Type
M&A
Amount
$60,000,000
M&A Terms
Takeda will acquire LigoCyte for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2155 Analysis Drive
Bozeman, MT 59718
USA
Email Address
Overview
LigoCyte is breaking new ground in the treatment of inflammatory and infectious disease. We have produced a number of novel drug compounds to modify immune responses by focusing on cell binding interactions and their role in the immune system.
Profile
LigoCyte Pharmaceuticals LinkedIn Company Profile
Social Media
LigoCyte Pharmaceuticals Company Twitter Account
Company News
LigoCyte Pharmaceuticals News
Facebook
LigoCyte Pharmaceuticals on Facebook
YouTube
LigoCyte Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Donald Beeman
  Donald Beeman LinkedIn Profile  Donald Beeman Twitter Account  Donald Beeman News  Donald Beeman on Facebook
Chief Medical Officer
Paul Mendelman
  Paul Mendelman LinkedIn Profile  Paul Mendelman Twitter Account  Paul Mendelman News  Paul Mendelman on Facebook
Chief Scientific Officer
Robert Bargatze
  Robert Bargatze LinkedIn Profile  Robert Bargatze Twitter Account  Robert Bargatze News  Robert Bargatze on Facebook
Controller
Larry Mikkola
  Larry Mikkola LinkedIn Profile  Larry Mikkola Twitter Account  Larry Mikkola News  Larry Mikkola on Facebook
President
Robert Goodwin
  Robert Goodwin LinkedIn Profile  Robert Goodwin Twitter Account  Robert Goodwin News  Robert Goodwin on Facebook
VP - R & D
Charles Richardson
  Charles Richardson LinkedIn Profile  Charles Richardson Twitter Account  Charles Richardson News  Charles Richardson on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/8/2012: Tolera Therapeutics venture capital transaction
Next: 10/8/2012: Xeround venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary